AVR

Anteris Technologies Global Corp.

Health Care Equipment & Services

Anteris Technologies Ltd specializes in developing advanced heart valve technologies, focusing on delivering innovative solutions to address unmet medical needs in cardiac surgery. Positioned as a frontrunner in the heart valve market, Anteris leverages its proprietary ADAPT tissue technology and DurAVR 3D single-piece aortic heart valves to enhance patient outcomes. The company's unique value lie...

heart valves

medical devices

biotechnology

healthcare innovation

Shorted

short percentage0.03%

reported shorts4.8K

shares on issue15.822M

About

website

anteristech.com

industry

Health Care Equipment & Services

address

Toowong Tower, Level 3, 9 Sherwood Rd, TOOWONG, QLD, AUSTRALIA, 4066

Connect

Key Metrics

market cap

$910.39M

price$8.61

eps$-3.73

employees

136

More Health Care Equipment & Services Stocks

Other shorted stocks in this sector

View all stocks in this industry

Short Position Trends

Track bearish sentiment and short interest over time

Historical Price Data

View stock price movements, volume, and trading patterns

Industry & Focus

heart valves

medical devices

biotechnology

healthcare innovation

ASX-listed

Company Overview

AI-generated company summary

Company History

Established in 1995, Anteris Technologies Ltd, formerly known as Admedus, initially focused on investing in and delivering breakthrough medical technologies. The company rebranded to Anteris Technologies in 2020 to reflect its renewed focus on heart valve solutions. A significant milestone was the development and commercialization of its proprietary ADAPT tissue technology. The company was listed on the ASX in November 1995, marking its entrance as a healthcare innovator in the Australian market.

Competitive Advantages

Anteris Technologies' primary competitive advantages include its proprietary ADAPT tissue technology, which offers superior durability and safety in heart valve replacement. Additionally, the company benefits from strategic partnerships and collaborations that enhance research capabilities and market reach.

Risk Factors

•Dependence on a limited product range primarily focused on heart valve technologies.
•Challenges in regulatory approvals that could delay product launches and market adoption.
•Highly competitive market with established players which could impact market share.

Recent Developments

Last 6 months

In the past six months, Anteris Technologies has announced successful pre-clinical results for its DurAVR aortic replacement valve, showing potential for improved hemodynamic performance. Additionally, the company has secured further investment funding to accelerate clinical trials and commercialization efforts.

Key People

Leadership team at Anteris Technologies Global Corp.

Wayne Paterson

CEO

Wayne Paterson has been CEO of Anteris Technologies since 2018. With a strong background in global leadership in healthcare, he has held senior roles at Bayer Healthcare and Merck, bringing extensive industry experience in strategic management and operations.

Christopher Pauly

CFO

Christopher Pauly joined Anteris Technologies as CFO, bringing over two decades of financial leadership experience in diverse industries, ensuring robust fiscal management and strategic planning within the company.

Financial Reports

10 reports available

2024 Financial Results and Corporate Update

Financial ReportMar 13, 2025via asx_announcements

Annual Report to shareholders

Annual ReportMar 13, 2025via asx_announcements

ASX waiver from requirement to lodge an Appendix 4E

Annual ResultsFeb 28, 2025via asx_announcements

Quarterly Activities/Appendix 4C Cash Flow Report

Quarterly ReportOct 31, 2024via asx_announcements

Half Yearly Report and Accounts

Half Year ResultsAug 22, 2024via asx_announcements

Quarterly Activities/Appendix 4C Cash Flow Report

Quarterly ReportJul 31, 2024via asx_announcements

Quarterly Activities/Appendix 4C Cash Flow Report

Quarterly ReportApr 18, 2024via asx_announcements

Annual Report to shareholders

Annual ReportApr 15, 2024via asx_announcements

Preliminary Final Report

Annual ResultsFeb 28, 2024via asx_announcements

Quarterly Activities/Appendix 4C Cash Flow Report

Quarterly ReportJan 31, 2024via asx_announcements